Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.32B 11.35B 10.61B 19.9B 1,323B 20.27B 136B 52.74B 652B 52.65B 51.5B 2,267B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.45B 10.55B 9.87B 18.5B 1,230B 18.84B 127B 49.03B 606B 48.96B 47.89B 2,107B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 31/03/2022
Compliance Officer 64 01/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
01/04/25Issuer sale

EVP, Chief Commercial Officer

167,824 0.1578%
01/04/25Issuer sale

Director

55,511 0.0522%
01/04/25Issuer sale

Director

52,606 0.0495%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+106.73% 14.02B
-0.53%+1.67%+19.19%-20.47% 63.09B
+0.63%+2.97%+51.92%+206.64% 55.61B
+0.07%+38.60%+38.60%+38.60% 41.64B
-1.54%-0.50%-51.77%-58.66% 38.98B
+1.19%+2.74%+58.64%-29.02% 29.82B
-1.11%-6.58%+122.45%-49.58% 23.71B
-0.86%+9.48%+59.19%+72.19% 21.48B
-0.85%0.00%-4.13%+143.06% 16.87B
-0.25%+6.77%+69.55%+122.96% 16.74B
Average -0.35%+2.68%+36.36%+53.25% 32.2B
Weighted average by Cap. -0.28%+2.78%+33.25%+46.58%

Financials

2023 2024
Net sales 464M 408M 376M 351M 659M 43.82B 671M 4.51B 1.75B 21.6B 1.74B 1.71B 75.06B 681M 598M 551M 515M 966M 64.25B 984M 6.61B 2.56B 31.67B 2.56B 2.5B 110B
Net income -140M -123M -113M -106M -198M -13.18B -202M -1.36B -525M -6.5B -525M -513M -22.58B -74.68M -65.6M -60.44M -56.51M -106M -7.05B -108M -725M -281M -3.47B -280M -274M -12.07B
Net Debt -481M -423M -389M -364M -683M -45.39B -695M -4.67B -1.81B -22.37B -1.81B -1.77B -77.75B -984M -864M -796M -745M -1.4B -92.86B -1.42B -9.56B -3.7B -45.77B -3.7B -3.61B -159B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock